EVALUATION OF THE RISK OF METASTATIC RELAPSE IN BREAST CANCER PATIENTS

摘要

The invention relates to an in vitro process for determining the prognosis of a primary breast cancer tumor in a patient, comprising the following steps: a) Assessing the level of expression of BCL-2 L10 protein in a sample of said breast cancer tumor from said patient; b) Comparing said level of expression with at least one reference value chosen among (i) a value representative of "BCL-2 L10 negative tumors", (ii) a value representative of "BCL-2 L10 positive tumors" and (iii) a cut-off value; c) Identifying said tumor as being "BCL-2 L10 negative" or "BCL-2 L10 positive", wherein if said tumor is identified in step (c) as being BCL2-L10 positive, said patient is classified as presenting a shorter distant metastasis free survival (DMFS).